Matti Marklund, Sari Voutilainen, Claudine Berr, Nicholas J. Wareham, Dariush Mozaffarian, Albert Koulman, Cécilia Samieri, Ingeborg A. Brouwer, Jenna Veenstra, Amanda M. Fretts, Luc Djoussé, David S. Siscovick, V. Gudnason, Lynne E. Wagenknecht, Lyn M. Steffen, Maria Lankinen, Michael Y. Tsai, Nathan L. Tintle, Nona Sotoodehnia, Jyrki K. Virtanen, Fumiaki Imamura, Barbara McKnight, Catherine Helmer, Kuo-Liong Chien, Kerry L. M. Wong, Jason H Y Wu, Rozenn N. Lemaitre, Bill Harris, Chaoyu Yu, Renata Micha, Matti Uusitupa, Tamara B. Harris, Kalina Rajaobelina, Nita G. Forouhi, Alexis C. Wood, Waqas Qureshi, Rachel A. Murphy, Markku Laakso, Brian T. Steffen, Anya Kalsbeek, Cardiovascular Health Research Unit [Seattle, WA, USA] (Department of Medicine), University of Washington [Seattle], MRC Integrative Epidemiology Unit [Bristol, Royaume-Uni] (MRC IEU), University of Bristol [Bristol], Departments of Epidemiology and Nutrition, Harvard School of Public Health, MRC Epidemiology Unit, University of Cambridge [UK] (CAM)-Institute of Metabolic Science, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), National Institute on Aging [Bethesda, USA] (NIA), National Institutes of Health [Bethesda] (NIH), MRC epidemiology Unit, Addenbrooke's Hospital, Department of Medicine, Kuopio University Hospital, NIHR Core Metabolomics and Lipidomics Laboratory, University of Cambridge, Epidémiologie, santé publique et développement, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR99-ISPED, Icelandic Heart Association, Kopavogur, Iceland., School of Public Health and Clinical Nutrition, University of Eastern Finland, Laboratory Medicine and Pathology in Minnesota [Rochester], Mayo Clinic, Institute of Public Health and Clinical Nutrition, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Berr, Claudine, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition and Health, APH - Health Behaviors & Chronic Diseases, and APH - Mental Health
International audience; BACKGROUND:Saturated fatty acids (SFAs) of different chain lengths have unique metabolic and biological effects, and a small number of recent studies suggest that higher circulating concentrations of the very-long-chain SFAs (VLSFAs) arachidic acid (20:0), behenic acid (22:0), and lignoceric acid (24:0) are associated with a lower risk of diabetes. Confirmation of these findings in a large and diverse population is needed.OBJECTIVE:We investigated the associations of circulating VLSFAs 20:0, 22:0, and 24:0 with incident type 2 diabetes in prospective studies.METHODS:Twelve studies that are part of the Fatty Acids and Outcomes Research Consortium participated in the analysis. Using Cox or logistic regression within studies and an inverse-variance-weighted meta-analysis across studies, we examined the associations of VLSFAs 20:0, 22:0, and 24:0 with incident diabetes among 51,431 participants.RESULTS:There were 14,276 cases of incident diabetes across participating studies. Higher circulating concentrations of 20:0, 22:0, and 24:0 were each associated with a lower risk of incident diabetes. Pooling across cohorts, the RR (95% CI) for incident diabetes comparing the 90th percentile to the 10th percentile was 0.78 (0.70, 0.87) for 20:0, 0.84 (0.77, 0.91) for 22:0, and 0.75 (0.69, 0.83) for 24:0 after adjustment for demographic, lifestyle, adiposity, and other health factors. Results were fully attenuated in exploratory models that adjusted for circulating 16:0 and triglycerides.CONCLUSIONS:Results from this pooled analysis indicate that higher concentrations of circulating VLSFAs 20:0, 22:0, and 24:0 are each associated with a lower risk of diabetes.